A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Lenalidomide (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 15 Mar 2012 Biomarkers information updated
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.